Metronomic therapy focused on muscarinic receptors could be useful on triple negative breast tumors, MDA-MB231 and MDA-MB468

OBREGON J; SALES, M E; SANCHEZ, Y; SANCHEZ, F; SALEM, A R; ESPANOL, A J

Mar del Plata

Congreso; S A I C . S A F E . S A B . SAP 2 0 1 9; 2019

SAIC-SAFE-SAB-SAP

The treatment of triple negative (TN) breast tumors is a problem not yet resolved in oncology, due to the lack of specific therapeutic targets. We had previously demonstrated that in vivo treatment with low doses of paclitaxel (PX) combined with the muscarinic agonist carbachol (Carb) reduced the growth of MDA-MB231 tumors in NUDE mice. The participation of muscarinic acetylcholine receptors (mAChRs) was demonstrated by reducing the effect observed by the administration of the muscarinic antagonist atropine (AT). In this work we analyzed the effect of PX or doxorubicin (DOXO), both drugs often used in the treatment of breast cancer combined with two different agonists: Carb or arecaidine propargyl esther (APE) all in suboptimal concentrations, on the viability of MDA-MB231 and MDA-MB468 tumors measured with by the MTT reagent. We observed that the combination of PX (10-8/10-9 M) + Carb (10-12/10-10 M) reduces the viability of MDA-MB231 and MDA-MB468 cells (36.8±6.2; p